Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma

Corren, Jonathan; Castro, Mario; Chanez, Pascal; Fabbri, Leonardo M.; Joish, Vijay N.; Amin, Nikhil; Graham, Neil M.H.; Mastey, Vera; Abbé, Adeline; Taniou, Christine; Mahajan, Pooja; Teper, Ariel; Pirozzi, Gianluca; Eckert, Laurent

doi:10.1016/j.anai.2018.08.005

Cited by 59 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 The overall proportion of responders in the placebo group was high but comparable with observations from studies of other biologic treatments for asthma, in which the proportions of placebo group patients achieving clinically meaningful improvements in ACQ-6 and AQLQ(S)+12 scores were 61-78% and 70-77%, respectively. [31][32][33][34] It can be hypothesized that the high proportion of placebo group responders in these studies may be a result of increased J o u r n a l P r e -p r o o f adherence to standard-of-care treatments while participating in the studies. Additionally, several studies have demonstrated that the perceived benefits of clinical trial enrollment from the patient's perspective can induce a positive response to a placebo treatment.…”

Section: Discussionmentioning

confidence: 99%

Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY

Corren

Gil

Griffiths

et al. 2021

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussionmentioning

confidence: 99%

Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY

Corren

Gil

Griffiths

et al. 2021

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a recent post-hoc analysis of a phase 2 study (NCT01854047), dupilumab produced a significant and clinically meaningful improvement in asthma symptom control as assessed via ACQ-5, AM/PM Asthma Symptoms Score, QoL, and productivity in an intention-to-treat population who received the drug administered at a dose of 200/300 mg every 2 weeks [62]. Another post-hoc analysis of the same study (NCT01854047) indicated that dupilumab 200 mg and 300 mg administered every 2 weeks significantly (P \ 0.05) reduced the rate of severe exacerbations and significantly (P \ 0.05) improved lung function, asthma control, and QoL compared to placebo, regardless of the exacerbation history of the patient [63].…”

Section: Dupilumabmentioning

confidence: 99%

Severe Asthma and Biological Therapy: When, Which, and for Whom

et al. 2019

View full text Add to dashboard Cite

Asthma is a heterogeneous chronic inflammatory disease of the airways that affects approximately 300 million people worldwide. About 5-10% of all asthmatics suffer from severe or uncontrolled asthma, associated with increased mortality and hospitalization, reduced quality of life, and increased health care costs. In recent years, new treatments have become available, and different asthma phenotypes characterized by specific biomarkers have been identified. Biological drugs are currently indicated for patients with severe asthma that is not controlled with recommended treatments. They are mostly directed against inflammatory molecules of the type 2 inflammatory pathway and are effective at reducing exacerbations, maintaining control over asthma symptoms, and reducing systemic steroid use, which is associated with well-known adverse events. Although biological drugs for severe asthma have had a major impact on the management of the disease, there is still a need for head-to-head comparison studies of biologics and to identify new biomarkers for asthma diagnosis, prognosis, and response to treatment. Identifying novel biomarkers could facilitate the development of therapeutic strategies that are precisely tailored to each patient's requirements.

show abstract

“…In patients with a FeNO of 50 ppb or more, the difference as compared with matched placebo was 0.39 liters. In a post hoc analysis, the greatest treatment benefit as compared with placebo was observed in patients with elevated type 2 biomarkers (both baseline blood eosinophil count of ≥150 per cubic millimeter and baseline FeNO ≥25 ppb) 44 .…”

Section: Dupilumabmentioning

confidence: 95%